COMMUNIQUÉS West-GlobeNewswire

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
15/04/2024
Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations Additionally, the company initiated an extension cohort to [...]
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
15/04/2024
MONTREAL, April 15, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of [...]
Theratechnologies annonce l’envoi de sa circulaire de sollicitation de procurations en vue de l’assemblée annuelle des actionnaires
15/04/2024
MONTRÉAL, 15 avr. 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une entreprise biopharmaceutique axée sur la mise au point et la commercialisation [...]
GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents
15/04/2024
Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients [...]
GENFIT : Assemblée Générale Mixte du 22 mai 2024 — modalités de mise à disposition des documents préparatoires
15/04/2024
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 15 avril 2024 – GENFIT (Nasdaq et Euronext : GNFT) , société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie [...]
Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort
15/04/2024
The expansion trial is expected to enrol 10 patients with bile tract cancers (cholangiocarcinoma) Interim results from the MAST trial have demonstrated positive responses in gastrointestinal cancers, particularly in [...]
SI-BONE To Report First Quarter 2024 Financial Results on May 6, 2024
15/04/2024
SANTA CLARA, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy today announced it will report [...]
Teladoc Health Provides Updated Start Time for First Quarter 2024 Earnings Call on April 25
15/04/2024
PURCHASE, NY, April 15, 2024 (GLOBE NEWSWIRE) -- Teladoc Health , Inc. (NYSE: TDOC), the global leader in whole-person virtual care, announced today that the conference call to review its first quarter 2024 results, [...]
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
15/04/2024
APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN 1 IgAN is a heterogeneous, progressive, rare kidney disease and [...]
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
15/04/2024
Bagsværd, Denmark, 15 April 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance [...]
Ezra, AI Leader in the Full Body MRI Space, Announces Partnership with Imaging Leader RAYUS Radiology
15/04/2024
The partnership will offer nationwide access to Ezra’s full-body MRI at 150 RAYUS locations across the country NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Ezra , the healthcare AI startup transforming early cancer [...]
Publication Annual Report – Annual Shareholders' Meeting
15/04/2024
Publication Annual Report – Annual Shareholders' Meeting Leuven, BELGIUM – April 15, 2024 – 05:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, has today published its [...]
Nika Pharmaceuticals, Inc. (NKPH) Purchased the Technologies for Three Drugs in Tablet Form and One Dietary Supplement
15/04/2024
HENDERSON, Nev., April 15, 2024 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH ) announces the purchase of four technologies for production of three generic drugs in tablet form and one dietary supplement [...]
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
15/04/2024
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory AL amyloidosis will be presented in Baltimore May 7-11, 2024 LOS ANGELES, April 15, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: [...]
Redemption Date Announced for Warrants
15/04/2024
Monday, May 6, 2024 is Last and Final Day to Exercise Warrants. Once Redeemed, the Warrants Will Cease to Exist and Have No Value. AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA [...]
Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary Products
15/04/2024
An important step in Kane becoming a market leader in the growing high-value wound care and dermatological markets WINNIPEG, Manitoba, April 15, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“ [...]
LifeLabs Celebrates National Medical Laboratory Week Recognizing Compassionate, Passionate, and Innovative Professionals
15/04/2024
Toronto, April 15, 2024 (GLOBE NEWSWIRE) -- This week, LifeLabs joins in celebrating the annual National Medical Laboratory Week, a significant event organized by the Canadian Society for Medical Laboratory Science. [...]
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
15/04/2024
Clinical trial expected to commence in mid-2024 to evaluate the safety and preliminary anti-tumor activity of TTX-MC138 BOSTON, April 15, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA [...]
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
15/04/2024
OCALA, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced that Charles Lapp, MD, is joining the company to help lead its efforts to develop Ampligen (rintatolimod) [...]

Pages